Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bayer Aktienges ADR
(OP:
BAYRY
)
7.810
+0.130 (+1.69%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
January 30, 2024
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
January 29, 2024
"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.
Via
Benzinga
Exposures
Glyphosate
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
January 08, 2024
Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)
Via
Benzinga
Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
January 04, 2024
Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.
Via
Benzinga
Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024
January 03, 2024
One of the hottest topics among members of Congress and investors has been the stock and options trading activity by several politicians.
Via
Benzinga
Best 4 Agriculture Companies For Your 2024 Investment Portfolio
December 27, 2023
Agriculture is and remains, a crucial sector for sustaining life, offering investors diverse opportunities in this vital industry.
Via
Talk Markets
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
December 26, 2023
In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
December 19, 2023
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience...
Via
Benzinga
Topics
Climate Change
Exposures
Climate
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
December 06, 2023
Bayer AG (OTC: BAYRY) (OTC:
Via
Benzinga
Exposures
Glyphosate
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
December 04, 2023
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
November 28, 2023
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Battered Blue-Chip Stocks to Sell in December
November 28, 2023
Steer clear of these once flourishing companies, each of which has problems they need to overcome before their share price rises again.
Via
InvestorPlace
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
November 24, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about...
Via
Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
November 20, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
November 17, 2023
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
November 08, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced
Via
Benzinga
Earnings Review: Bayer To Make Strategic Changes After Q3 Results
November 08, 2023
The latest financial statements from Bayer Group show a year-over-year decline in several key areas, painting a stark picture of the company’s fiscal health.
Via
Talk Markets
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
November 01, 2023
Bayer AG (OTC: BAYRY) (OTC:
Via
Benzinga
Exposures
Glyphosate
Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
September 27, 2023
Investors tend to closely watch which Cathie Wood stocks are bought and sold as she has history of generating big returns in her ETFs
Via
InvestorPlace
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
September 12, 2023
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for...
Via
Benzinga
Exposures
Product Safety
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
August 28, 2023
Reuters
Via
Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
August 28, 2023
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields...
Via
Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
August 21, 2023
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),
Via
Benzinga
Exposures
Product Safety
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 08, 2023
Tiziana Life Sciences, Inc.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.